Core Viewpoint - Cassava Sciences, Inc. has appointed Dr. Joseph Hulihan as Chief Medical Officer to lead the clinical development of simufilam for Tuberous Sclerosis Complex (TSC)-related epilepsy [1][3][8] Company Overview - Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing investigational treatments for central nervous system disorders, including TSC-related epilepsy [5] - Simufilam is a proprietary oral small molecule believed to modulate the activity of the filamin A protein, which is crucial for neuronal development [5] Appointment of Dr. Joseph Hulihan - Dr. Hulihan has over 25 years of experience in the development of therapeutics for epilepsy and neurological disorders, previously serving as CMO at Marinus Pharmaceuticals and in senior roles at Janssen Pharmaceuticals [2][4] - He is board certified in Neurology and Electroencephalography (EEG) and has been involved in over 25 late-stage neurology-focused clinical trials [2][4] Clinical Development Plans - The clinical program for simufilam as a potential treatment for TSC-related epilepsy is set to begin in the first half of 2026 [4][8] - Dr. Hulihan expressed enthusiasm for simufilam's novel mechanism of action and the upcoming proof-of-concept study [4]

Core Viewpoint - Ovid Therapeutics has entered into a definitive agreement with Immedica Pharma for the sale of future royalties related to ganaxolone sales outside of China, providing Ovid with a non-dilutive capital infusion of $7 million to support its ongoing operations [1][2]. Group 1: Transaction Details - Immedica will pay $7 million in cash to acquire 100% of the royalty rights held by Ovid, enhancing Immedica's focus on ganaxolone by gaining control of additional intellectual property rights [1]. - The transaction includes royalties associated with a previous agreement Ovid had with Marinus Pharmaceuticals regarding ganaxolone for CDKL5 deficiency disorder [4]. - Ovid recorded approximately $566,000 in ganaxolone royalty revenues in 2024, indicating the current revenue scale from this asset [2]. Group 2: Company Backgrounds - Ovid Therapeutics is a biopharmaceutical company focused on developing small molecule medicines for brain conditions with significant unmet needs, advancing a pipeline of novel candidates targeting neurological disorders [7]. - Immedica is a pharmaceutical company dedicated to the commercialization of medicines for rare diseases, with a global distribution network serving patients in over 50 countries [6].

Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "expect", "anticipate", ...